Advertisement

Topics

Dendreon Adds $80M, Amgen Advances ‘Son of Dmab,’ Mobisante Wins FDA OK, & More Seattle-Area Life Sciences News

04:10 EST 10 Feb 2011 |

My favorite team, the Green Bay Packers, won the Super Bowl on Sunday. So it’s kind of amazing I was able to concentrate on work at all this week. I’m beginning to think there’s a Green & Gold glow coming out of my skin, as a matter of fact. —Seattle-based Dendreon (NASDAQ: DNDN) tacked on [...]

Original Article: Dendreon Adds $80M, Amgen Advances ‘Son of Dmab,’ Mobisante Wins FDA OK, & More Seattle-Area Life Sciences News

NEXT ARTICLE

More From BioPortfolio on "Dendreon Adds $80M, Amgen Advances ‘Son of Dmab,’ Mobisante Wins FDA OK, & More Seattle-Area Life Sciences News"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...